How has been the historical performance of Piramal Pharma?

Answer:The historical performance of Piramal Pharma shows a fluctuating trend in key financial metrics over the past four years.

Breakdown:
Piramal Pharma's net sales have consistently increased from INR 6,559.10 crore in March 2022 to INR 9,151.18 crore in March 2025. Total operating income followed a similar upward trajectory, reaching INR 9,151.18 crore in March 2025, up from INR 6,559.10 crore in March 2022. However, total expenditure also rose significantly, from INR 5,609.44 crore in March 2022 to INR 7,706.35 crore in March 2025. Operating profit (PBDIT) showed improvement, climbing from INR 1,225.46 crore in March 2022 to INR 1,579.64 crore in March 2025, while profit before tax rebounded to INR 341.71 crore in March 2025 after a loss of INR 174.48 crore in March 2023. The profit after tax turned positive at INR 18.20 crore in March 2025, contrasting with losses in the previous two years. Consolidated net profit also improved to INR 91.13 crore in March 2025, following a loss of INR 186.46 crore in March 2023. The company's total assets increased from INR 12,499.77 crore in March 2022 to INR 15,284.46 crore in March 2025, while total liabilities rose from INR 12,499.77 crore to INR 15,284.46 crore in the same period. Cash flow from operating activities was INR 892.00 crore in March 2025, down from INR 1,004.00 crore in March 2024, indicating a decline in cash generation despite the increase in sales. Overall, while Piramal Pharma has shown growth in sales and profits, it has faced challenges in maintaining cash flow stability.